PointState Capital’s Kyntra Bio KYNB Stock Holding History

PointState Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-32,408	Closed	-$50.7M	–	158
2018 Q2	$50.7M	Buy	32,408 +15,532	+92%	+$20.2M	0.57%	44
2018 Q1	$19.5M	Buy	+16,876	New	+$22.2M	0.21%	74
2017 Q1	–	Sell	-33,068	Closed	-$17.7M	–	142
2016 Q4	$17.7M	Buy	33,068 +17,068	+107%	+$8.52M	0.25%	75
2016 Q3	$8.28M	Buy	16,000 +2,000	+14%	+$942K	0.09%	92
2016 Q2	$5.74M	Hold	14,000	–	–	0.12%	64
2016 Q1	$7.45M	Buy	+14,000	New	+$6.98M	0.2%	47
2015 Q2	–	Sell	-35,165	Closed	-$22.1M	–	161
2015 Q1	$22.1M	Hold	35,165	–	–	0.3%	64
2014 Q4	$19.2M	Buy	+35,165	New	+$22.6M	0.33%	65

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PointState Capital's KYNB Position: Q3 2018 in Review

PointState Capital sold out of Kyntra Bio (KYNB) in Q3 2018, closing a stake of 32,408 shares — an estimated $50.7M sold.

PointState Capital first reported a position in KYNB in Q4 2014 and held it in 8 quarters. The position peaked at $50.7M in Q2 2018. 187 funds tracked by Wall St. Rank hold KYNB as of Q3 2018.

PointState Capital reported no remaining Kyntra Bio position as of Q3 2018 after selling out during the quarter.
PointState Capital sold 32,408 Kyntra Bio shares in Q3 2018, an estimated $50.7M.
PointState Capital first reported a position in Kyntra Bio in Q4 2014 and held it in 8 quarters.
PointState Capital's Kyntra Bio position peaked at $50.7M in Q2 2018.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.